IMUC Share Price

Open 2.58 Change Price %
High 2.89 1 Day -0.02 -0.75
Low 2.55 1 Week -0.24 -8.28
Close 2.66 1 Month 2.58 3225.00
Volume 97974 1 Year 2.24 533.33
52 Week High 3.55
52 Week Low 0.06
IMUC Important Levels
Resistance 2 2.98
Resistance 1 2.85
Pivot 2.70
Support 1 2.47
Support 2 2.34
AMEX USA Most Active Stocks
PAL 0.05 -50.00%
PAL 0.05 -50.00%
PAL 0.05 -50.00%
CVM 0.11 -38.89%
CVM 0.11 -38.89%
PLX 0.31 -44.64%
PLX 0.31 -44.64%
RBY 0.03 -70.00%
NAK 1.45 21.85%
NAK 1.45 21.85%
More..
AMEX USA Top Gainers Stocks
GGR 0.02 100.00%
CMFO 0.12 100.00%
ATC 0.37 60.87%
ATC 0.37 60.87%
ATC 0.37 60.87%
ATC 0.37 60.87%
MBA 0.20 25.00%
MBA 0.20 25.00%
MBA 0.20 25.00%
IG 7.68 22.49%
More..
AMEX USA Top Losers Stocks
RBY 0.03 -70.00%
PAL 0.05 -50.00%
PAL 0.05 -50.00%
PAL 0.05 -50.00%
RVP 1.30 -46.94%
PLX 0.31 -44.64%
PLX 0.31 -44.64%
CVM 0.11 -38.89%
CVM 0.11 -38.89%
QBC 0.20 -33.33%
More..

ImmunoCellular Therapeutics, Ltd. (AMEX: IMUC)

IMUC Technical Analysis 5
As on 2nd Dec 2016 IMUC Share Price closed @ 2.66 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 0.32 & Strong Buy for SHORT-TERM with Stoploss of 0.57 we also expect STOCK to react on Following IMPORTANT LEVELS.
IMUC Target for December
1st Target up-side 4.79
2nd Target up-side 6.13
3rd Target up-side 7.46
1st Target down-side 0.99
2nd Target down-side -0.35
3rd Target down-side -1.68
IMUC Other Details
Segment EQ
Market Capital 79347032.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.imuc.com
IMUC Address
IMUC
23622 Calabasas Road
Suite 300
Calabasas, CA 91302
United States
Phone: 818-264-2300
Fax: 818-224-5287
IMUC Latest News
Interactive Technical Analysis Chart ImmunoCellular Therapeutics, Ltd. ( IMUC AMEX USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on ImmunoCellular Therapeutics, Ltd.
IMUC Business Profile
ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company, develops immune-based therapies for the treatment of brain and ovarian cancers. Its lead product candidate includes ICT-107, a dendritic cell (DC) vaccine that completed completed Phase II testing trials for the treatment of glioblastoma multiforme (GBM). The company also develops other therapeutic DC vaccines, such as ICT-121 to treat recurrent GBM and other solid tumor cancers, as well as ovarian, pancreatic, and breast cancers; and ICT-140 that targets 7 tumor-associated antigens expressed on ovarian cancer cells. In addition, it has a differential immunization for antigen and antibody discovery platform for discovering monoclonal antibodies for therapeutic and diagnostic development. The company was formerly known as Optical Molecular Imaging, Inc. and changed its name to ImmunoCellular Therapeutics, Ltd. in November 2006. ImmunoCellular Therapeutics, Ltd. is based in Calabasas, California.